Rubicon Research Limited has informed the Exchange about General Updates

Regulatory & Legal View source PDF Explain this filing

RUBICON · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.5%Reaction day

₹937.80

prior close

₹951.30

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+2.4%+0.1% vs market

Pharmaceuticals peers, median of 163sector+0.9%+1.5% vs sector

On the reaction day the stock moved 0.1 pts more than Nifty Microcap 250 and 1.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.7

10m

+1.2

15m

+0.9

30m

+0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.5+2.4+0.1+0.9+1.5

Next day

+2.1+2.2-0.2+0.8+1.3

+3.7+2.2+1.4+0.3+3.4

+2.8+1.9+0.9+0.4+2.5

+3.9+3.4+0.6+0.8+3.1

+3.4+3.3+0.1+0.7+2.7

+1.3+6.6-5.3+3.3-2.0

15d

+4.6+1.4+3.2+2.4+2.3

+3.5+5.6-2.0+4.3-0.8

+52.3+10.4+41.8+4.9+47.3

+67.8+12.1+55.8+8.2+59.7

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 163Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

USFDA conducted an unannounced inspection at Rubicon Research's R&D facility in Concord, Ontario, Canada from April 20-24, 2026. The inspection concluded successfully without any Form 483 being issued, which is a significant positive outcome. Form 483 is issued when FDA inspectors identify potential violations, so its absence indicates the facility met regulatory standards. The company stated it remains committed to maintaining compliance and quality standards.

Likely market impact

Positive development for shareholders as the clean inspection outcome removes regulatory risk and demonstrates the company's R&D operations meet USFDA standards, which is important for a pharma contract research company.